Enliven Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-0.38 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | $-0.32 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | – | $-0.46 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | $-0.41 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | $-0.54 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | After market close | – | $-0.47 | – |
Press releases
Announcements Enliven Therapeutics filed with the SEC
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K/A
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Enliven Therapeutics Announces Updated Positive Data from Phase 1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in
Other events · EX-99.1 to Form 8-K
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Shareholder vote results · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
Shareholder vote results · Other events · EX-99.2 to Form 8-K
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K/A
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K/A
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Material agreement · Acquisition or disposition completed · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
consider the risks described below. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ
Material agreement · Acquisition or disposition completed · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
“we,” “our,” “us”, “our company” and “Enliven” refer to Enliven Therapeutics, Inc. together with its subsidiaries (formerly, Imara Inc.). References to “Former Enliven” refer to Enliven
Material agreement · Acquisition or disposition completed · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.3 to Form 8-K
RESTATED 2020 EQUITY INCENTIVE PLAN
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
The 2020 Employee Stock Purchase Plan (the “Plan”) of IMARA Inc. is hereby amended as follows:
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.2 to Form 8-K
IMARA ANNOUNCES STOCKHOLDER APPROVAL OF MERGER WITH ENLIVEN
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.3 to Form 8-K
Enliven Therapeutics, Inc. and Imara Inc. Announce Definitive Merger Agreement
Other events · EX-99.1 to Form 8-K
Enliven Therapeutics and Imara Announce Merger Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
Merger Announcement October 13, 2022
Material agreement · Other events · EX-99.2 to Form 8-K
Imara Reports Full Year 2021 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K